1

Key Insights

2

Neuroendocrine Tumors Market Overview at a Glance

2.1

Market Share (%) Distribution of Neuroendocrine Tumors in 2017

2.2

Market Share (%) Distribution of Neuroendocrine Tumors in 2026

3

Executive Summary of Neuroendocrine Tumors

4

Neuroendocrine Tumors: Disease Background and Overview

4.1

Introduction

4.2

Causes

4.3

Pathophysiology

4.4

Symptoms

4.5

Risk Factors

4.6

Diagnosis

5

Diagnostic Algorithm for Neuroendocrine Tumors

6

Clinical Algorithm for Neuroendocrine Tumors

7

Epidemiology and Patient Population

7.1

Key Findings

7.2

Total Prevalent Population of Neuroendocrine Tumors

7.3

Total Diagnosed Prevalent Population of Neuroendocrine Tumors

7.4

Site-specific Diagnosed Prevalent Population of Neuroendocrine Tumors  

7.5

Age-specific Diagnosed Prevalent Population of Neuroendocrine Tumors

7.6

Gender-specific Diagnosed Prevalent Population of Neuroendocrine Tumors

7.7

Stage-wise Diagnosed Prevalent Population of Neuroendocrine Tumors

7.8

Grade-wise Diagnosed Prevalent Population of Neuroendocrine Tumors

8

Region Wise-Epidemiology of Neuroendocrine Tumors

8.1

Assumptions and Rationale

8.2

North America

8.2.1

Assumptions and Rationale

8.2.2

Total Prevalent Population of Neuroendocrine Tumors in the North America

8.2.3

Total Diagnosed Prevalent Population of Neuroendocrine Tumors in the North America

8.2.4

Site-specific Diagnosed Prevalent Population of Neuroendocrine Tumors in the North America

8.2.5

Age- specific Diagnosed Prevalent Population of Neuroendocrine Tumors in the North America

8.2.6

Gender-specific Diagnosed Prevalent Population of Neuroendocrine Tumors in the North America

8.2.7

Stage-wise Diagnosed Prevalent Population of Neuroendocrine Tumors in the North America

8.2.8

Grade-wise Diagnosed Prevalent Population of Neuroendocrine Tumors in the North America

8.3

Europe

8.3.1

Assumptions and Rationale

8.3.2

Total Prevalent Population of Neuroendocrine Tumors in Europe

8.3.3

Total Diagnosed Prevalent Population of Neuroendocrine Tumors in Europe

8.3.4

Site-specific Diagnosed Prevalent Population of Neuroendocrine Tumors in Europe

8.3.5

Age- specific Diagnosed Prevalent Population of Neuroendocrine Tumors in Europe

8.3.6

Gender-specific Diagnosed Prevalent Population of Neuroendocrine Tumors in Europe

8.3.7

Stage-wise Diagnosed Prevalent Population of Neuroendocrine Tumors in Europe

8.3.8

Grade-wise Diagnosed Prevalent Population of Neuroendocrine Tumors in Europe

8.4

Asia-Pacific

8.4.1

Assumptions and Rationale

8.4.2

Total Prevalent Population of Neuroendocrine Tumors in Asia-Pacific

8.4.3

Total Diagnosed Prevalent Population of Neuroendocrine Tumors in Asia-Pacific

8.4.4

Site-specific Diagnosed Prevalent Population of Neuroendocrine Tumors in Asia-Pacific

8.4.5

Age- specific Diagnosed Prevalent Population of Neuroendocrine Tumors in Asia-Pacific

8.4.6

Gender-specific Diagnosed Prevalent Population of Neuroendocrine Tumors in Asia-Pacific

8.4.7

Stage-wise Diagnosed Prevalent Population of Neuroendocrine Tumors in Asia-Pacific

8.4.8

Grade-wise Diagnosed Prevalent Population of Neuroendocrine Tumors in Asia-Pacific

8.5

Middle-East and Africa

8.5.1

Assumptions and Rationale

8.5.2

Total Prevalent Population of Neuroendocrine Tumors in Middle-East and Africa

8.5.3

Total Diagnosed Prevalent Population of Neuroendocrine Tumors in Middle-East and Africa

8.5.4

Site-specific Diagnosed Prevalent Population of Neuroendocrine Tumors in Middle-East and Africa

8.5.5

Age- specific Diagnosed Prevalent Population of Neuroendocrine Tumors in Middle-East and Africa

8.5.6

Gender-specific Diagnosed Prevalent Population of Neuroendocrine Tumors in Middle-East and Africa

8.5.7

Stage-wise Diagnosed Prevalent Population of Neuroendocrine Tumors in Middle-East and Africa

8.5.8

Grade-wise Diagnosed Prevalent Population of Neuroendocrine Tumors in Middle-East and Africa

8.6

South America

8.6.1

Assumptions and Rationale

8.6.2

Total Prevalent Population of Neuroendocrine Tumors in South America

8.6.3

Total Diagnosed Prevalent Population of Neuroendocrine Tumors in South America

8.6.4

Site-specific Diagnosed Prevalent Population of Neuroendocrine Tumors in South America

8.6.5

Age- specific Diagnosed Prevalent Population of Neuroendocrine Tumors in South America

8.6.6

Gender-specific Diagnosed Prevalent Population of Neuroendocrine Tumors in South America

8.6.7

Stage-wise Diagnosed Prevalent Population of Neuroendocrine Tumors in South America

8.6.8

Grade-wise Diagnosed Prevalent Population of Neuroendocrine Tumors in South America

9

Treatment

10

Treatment Algorithm (approaches for a particular disease) for Neuroendocrine Tumors

11

Marketed drugs

11.1

Afinitor (Everolimus): Novartis

11.1.1

Drug Description

11.1.2

Regulatory Milestones

11.1.3

Other Development Activities

11.1.4

Safety and Efficacy

11.1.5

Product profile

11.2

Sutent (Sunitinib Malate): Pfizer

11.2.1

Drug Description

11.2.2

Regulatory Milestones

11.2.3

Other Development Activities

11.2.4

Safety and Efficacy

11.2.5

Product profile

11.3

Somatuline Depot (Lanreotide): Ipsen Biopharmaceuticals Inc.

11.3.1

Drug Description

11.3.2

Regulatory Milestones

11.3.3

Other Development Activities

11.3.4

Safety and Efficacy

11.3.5

Product profile

Continued in the report...

12

Emerging Drugs

12.1

Surufatinib: Hutchison Medipharma Limited

12.1.1

Product Description

12.1.2

Other Development Activities

12.1.3

Clinical Development

12.1.4

Clinical TriNETs Information

12.1.5

Safety and Efficacy

12.1.6

Product Profile

12.2

177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen GmbH

12.2.1

Product Description

12.2.2

Other Development Activities

12.2.3

Clinical Development

12.2.4

Clinical TriNETs Information

12.2.5

Safety and Efficacy

12.2.6

Product Profile

12.3

Anlotinib: Advenchen Laboratories, LLC.

12.3.1

Product Description

12.3.2

Other Development Activities

12.3.3

Clinical Development

12.3.4

Clinical TriNETs Information

12.3.5

Safety and Efficacy

12.3.6

Product Profile

12.4.6

Product Profile

Continued in the report...

13

Neuroendocrine Tumors: Regional Market Analysis

13.1

Key Findings

13.2

Market Size of Neuroendocrine Tumors

14

The North America Market Outlook

14.1

North America Market Size

14.1.1

Total Market size of Neuroendocrine Tumors

14.1.2

Market Size by Site

14.1.3

Market Size by Treatment type

14.1.4

Market Size by Diagnostic tools

14.1.5

Market Size by End users

15

Europe: Market Outlook

15.1

Europe Market Size

15.1.1

Total Market size of Neuroendocrine Tumors

15.1.2

Market Size by Site

15.1.3

Market Size by Treatment type

15.1.4

Market Size by Diagnostic tools

15.1.5

Market Size by End users

16

Asia-Pacific Market Outlook

16.1

Asia-Pacific Market Size

16.1.1

Total Market size of Neuroendocrine Tumors

16.1.2

Market Size by Site

16.1.3

Market Size by Treatment type

16.1.4

Market Size by Diagnostic tools

16.1.5

Market Size by End users

17

Middle-East and Africa Market Outlook

17.1

Middle-East and Africa Market Size

17.1.1

Total Market size of Neuroendocrine Tumors

17.1.2

Market Size by Site

17.1.3

Market Size by Treatment type

17.1.4

Market Size by Diagnostic tools

17.1.5

Market Size by End users

18

South America Market Outlook

18.1

South America Market Size

18.1.1

Total Market size of Neuroendocrine Tumors

18.1.2

Market Size by Site

18.1.3

Market Size by Treatment type

18.1.4

Market Size by Diagnostic tools

18.1.5

Market Size by End users

19

Market Drivers

20

Market Barriers

21

SWOT Analysis of Neuroendocrine Tumors

22

Appendix

22.1

Report Methodology

23

About Report Ocean